Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    Vir Biotechnology | United States
Previous Study | Return to List | Next Study

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04725877
Recruitment Status : Recruiting
First Posted : January 27, 2021
Last Update Posted : January 27, 2021
Sponsor:
Collaborator:
Bill and Melinda Gates Foundation
Information provided by (Responsible Party):
Vir Biotechnology, Inc.

Brief Summary:
This is a Phase 1a, first in human study in which healthy adult participants who are considered to be at low-risk for HIV infection and are seropositive for cytomegalovirus (CMV) will receive two doses of VIR-1111 or placebo. These participants will be assessed for safety, reactogenicity, tolerability and immunogenicity. There is an optional long-term follow-up study that would lengthen study participation for up to 3 years post-first dose.

Condition or disease Intervention/treatment Phase
HIV I Infection Biological: VIR-1111 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1a, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers
Actual Study Start Date : December 28, 2020
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: VIR-1111 Biological: VIR-1111
VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.

Placebo Comparator: Placebo Drug: Placebo
A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.




Primary Outcome Measures :
  1. Number of participants with any treatment-emergent adverse events (AEs) [ Time Frame: Day 1 through 36 weeks ]
    A treatment-emergent AE is any AE with an onset date on or after the investigational product start date and no later than 36 weeks after permanent discontinuation of the investigational product.

  2. Number of participants with any serious AEs (SAEs) [ Time Frame: Day 1 through 36 weeks ]
    An SAE is any life-threatening event or one that results in hospitalization, significant disability/incapacity, death or congenital anomaly/birth defect.

  3. Number of participants with any local site reactogenicity event after first dose [ Time Frame: Day 1 through 14 days after first dose ]
    Signs and symptoms will be captured at the injection site (e.g., pain/tenderness, swelling, redness and induration) through self-assessment via participant diaries and in-person clinical assessments.

  4. Number of participants with any local site reactogenicity event after second dose [ Time Frame: Day 1 through 14 days after second dose ]
    Signs and symptoms will be captured at the injection site (e.g., pain/tenderness, swelling, redness and induration) through self-assessment via participant diaries and in-person clinical assessments.

  5. Number of participants with any systemic reactogenicity event after first dose [ Time Frame: Day 1 through 14 days after first dose ]
    Systemic signs and symptoms (fever, headache, fatigue, arthralgia, myalgia, malaise, nausea, vomiting or chills) through self-assessment via participant diaries and in-person clinical assessments.

  6. Number of participants with any systemic reactogenicity event after second dose [ Time Frame: Day 1 through 14 days after second dose ]
    Systemic signs and symptoms (fever, headache, fatigue, arthralgia, myalgia, malaise, nausea, vomiting or chills) through self-assessment via participant diaries and in-person clinical assessments.

  7. Number of participants with any treatment-emergent clinical laboratory abnormalities (chemistry, hematology and liver function tests) [ Time Frame: Day 1 through 36 weeks ]
    A treatment-emergent clinical laboratory abnormality is a clinical laboratory value that increases at least 1 toxicity grade from baseline at any postbaseline timepoint up to 30 days after permanent discontinuation of study drug. Clinical laboratory abnormalities are graded using DAIDS Table for Grading and Severity of Adult and Pediatric Events, Corrected Version 2.1, July 2017.

  8. Number of participants with CMV vector viremia (blood) [ Time Frame: Day 1 through 36 weeks ]
    Quantitative polymerase chain reaction (qPCR) for CMV will be performed on participant blood samples collected throughout the study. Positive samples will undergo follow-up confirmatory PCR testing to differentiate wild-type CMV from CMV vaccine vector sequences.

  9. Number of participants with CMV vector shedding (urine and saliva) [ Time Frame: Day 1 through 36 weeks ]
    Quantitative polymerase chain reaction (qPCR) for CMV will be performed on both saliva and urine samples collected from participants throughout the study to monitor for viral shedding. Positive samples will undergo follow-up confirmatory PCR testing to differentiate wild-type CMV from CMV vaccine vector sequences.


Secondary Outcome Measures :
  1. Frequency of CMV-specific CD4 T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect IL-2 AND/OR IFNg AND/OR TNFa [ Time Frame: 0-36 weeks ]
  2. Frequency of CMV-specific CD8 T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect IL-2 AND/OR IFNg AND/OR TNFa [ Time Frame: 0-36 weeks ]
  3. Frequency of HIV-1 Clade A Gag-specific CD4 T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect IL-2 AND/OR IFNg AND/OR TNFa [ Time Frame: 0-36 weeks ]
  4. Frequency of HIV-1 Clade A Gag-specific CD8 T cells T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect IL-2 AND/OR IFNg AND/OR TNFa [ Time Frame: 0-36 weeks ]
  5. Polyfunctionality of CMV-specific CD4 T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect all combinations of IL-2, IFNg, TNFa, CD154, IL-17, MIP-1b, CD107a AND/OR Granzyme B [ Time Frame: 0-36 weeks ]
  6. Polyfunctionality of CMV-specific CD8 T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect all combinations of IL-2, IFNg, TNFa, CD154, IL-17, MIP-1b, CD107a AND/OR Granzyme B [ Time Frame: 0-36 weeks ]
  7. Polyfunctionality of HIV-1 Clade A Gag-specific CD4 T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect all combinations of IL-2, IFNg, TNFa, CD154, IL-17, MIP-1b, CD107a AND/OR Granzyme B [ Time Frame: 0-36 weeks ]
  8. Polyfunctionality of HIV-1 Clade A Gag-specific CD8 T cells via peptide stimulation, intracellular cytokine staining and flow cytometry to detect all combinations of IL-2, IFNg, TNFa, CD154, IL-17, MIP-1b, CD107a AND/OR Granzyme B [ Time Frame: 0-36 weeks ]
  9. Memory phenotype of CMV-specific CD4 T cells via flow cytometry analysis of CD45RA, CCR7, CD27, CD28 AND/OR CD95. [ Time Frame: 0-36 weeks ]
  10. Memory phenotype of CMV-specific CD8 T cells via flow cytometry analysis of CD45RA, CCR7, CD27, CD28 AND/OR CD95 [ Time Frame: 0-36 weeks ]
  11. Memory phenotype of HIV-1 Clade A Gag-specific CD4 T cells via flow cytometry analysis of CD45RA, CCR7, CD27, CD28 AND/OR CD95 [ Time Frame: 0-36 weeks ]
  12. Memory phenotype of HIV-1 Clade A Gag-specific CD8 T cells via flow cytometry analysis of CD45RA, CCR7, CD27, CD28 AND/OR CD95 [ Time Frame: 0-36 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males or healthy females of non-child-bearing potential between the ages of 18 to 50 at the time of screening
  • Positive CMV serostatus
  • Assessed by clinic staff as being low risk for HIV infection and committed to maintaining behavior consistent with low risk of HIV exposure through the last protocol visit
  • Willing to use condoms during intercourse through Week 36 or the end of the study
  • Willing to undergo HIV testing, risk reduction counseling, and receive HIV test results
  • Willing to comply with the protocol requirements regarding donation of blood, sperm or other tissues
  • In the opinion of the Investigator, generally in good health as determined from medical history and no clinically significant findings from physical examinations, vital signs, and laboratory values

Exclusion Criteria:

  • Live in a home with children under the age of 6
  • Routine provision of child care to children under the age of 6
  • Have close contact with immunocompromised individuals
  • Have close contact with pregnant women or a partner planning to become pregnant during the course of the study
  • Health care provider who routinely comes into contact with immunosuppressed patients or pregnant women
  • Participant is immunocompromised
  • Participant has an autoimmune disorder
  • Positive HIV test at the time of study screening
  • Receipt of another investigational HIV or CMV vaccine candidate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04725877


Contacts
Layout table for location contacts
Contact: Study Inquiry +1 415-654-5281 clinicaltrials@vir.bio

Locations
Layout table for location information
United States, Massachusetts
Investigative Site Not yet recruiting
Boston, Massachusetts, United States, 02115
United States, Washington
Investigative Site Not yet recruiting
Seattle, Washington, United States, 98104
United States, Wisconsin
Investigative Site Recruiting
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Vir Biotechnology, Inc.
Bill and Melinda Gates Foundation
Layout table for additonal information
Responsible Party: Vir Biotechnology, Inc.
ClinicalTrials.gov Identifier: NCT04725877    
Other Study ID Numbers: VIR-1111-2001
First Posted: January 27, 2021    Key Record Dates
Last Update Posted: January 27, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Vir Biotechnology, Inc.:
HIV
Vaccine
CMV
Cytomegalovirus
Additional relevant MeSH terms:
Layout table for MeSH terms
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases